1. CD47 ASO reduces weight gain, fat mass, improves glucose tolerance, and alleviates steatosis.2. CD47 ASO treatment did not significantly alter the expression of UCP1, CPT1, or PGC1α in brown adipose tissue; cold tolerance remained unchanged, and no browning of white adipose tissue was observed.3. Reduced inflammatory cytokines (TNF-α, IL-1β), enhanced M2 macrophage polarization, CD47 ASO treatment also decreased CD8 expression in epididymal white adipose tissue. The gene discussed is PPARGC1A; the disease is steatosis.